- In March 2025, Baxter International Inc., a global leader in critical care solutions, announced the launch of its next-generation Propofol-based sedation infusion system for patients with severe traumatic brain injury (TBI). This system offers precise, real-time dosing adjustments based on continuous brain monitoring, improving the management of intracranial pressure (ICP) and reducing the risks of over-sedation. The system is designed to enhance patient safety and optimize sedation in ICU settings
- In December 2024, Fresenius Kabi unveiled a new barbiturate infusion solution designed to manage elevated ICP in TBI patients. The infusion system includes enhanced formulations for controlled coma induction, aimed at reducing brain swelling and preventing secondary brain damage. It also integrates with advanced monitoring systems to ensure the best therapeutic outcomes with minimal side effects
- In November 2024, Hospira (A subsidiary of Pfizer Inc.) presented clinical data on its Midazolam-based coma-inducing agents at the American Neurocritical Care Conference. The data highlighted its effectiveness in managing severe TBIs while minimizing respiratory depression and hypotension, common side effects of prolonged sedation. The company plans to expand availability in U.S. trauma centers by early 2025
- In October 2024, Merck & Co. announced a significant breakthrough in the development of neuroprotective sedatives for TBI patients. Their new experimental drug targets the underlying mechanisms of brain injury, providing neuroprotection while inducing a controlled coma. Early-stage clinical trials show promising results in improving survival rates and neurological recovery in TBI patients
- In September 2024, Teva Pharmaceutical Industries Ltd. launched a comprehensive sedation protocol using Propofol and Pentobarbital for patients in critical TBI care. This protocol is supported by advanced monitoring tools, including continuous intracranial pressure (ICP) monitoring, to reduce sedation-related complications and improve patient outcomes in ICU settings
